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Abstract 
Noncognitive symptoms in dementia include many kinds of behavioural and psychological symptoms. 
Behavioural  and  psychological  symptoms  of  dementia,  BPSD,  is  quite  common  problem  among 
individuals  with  dementia,  and  often  difficult  to  manage.  BPSD  can  lead  to  premature 
institutionalization and decreased quality of life for both the caregiver and the patient. The purpose 
of this paper is to review and describe the main characteristics of dementia and to get an overall 
view of the management and treatment of the behavioural and psychological problems in dementia. 
There  is  consensus  about  that  the  nonpharmacologic  interventions  should  allways  be  tried  first 
before starting any medication for BPSD. However, it is exactly the efficacy of nonpharmacologic 
interventions  that  lack  the  the  scientific  proof  in  long  term;  more  controlled  trials  are  needed. 
Pharmacotherapies are used frequently to treat BPSD. Pharmacologic interventions are necessary 
when nonpharmacologic  strategies  fail  to  reduce behavioral  symptoms sufficiently.  For  the  time 
being  pharmacolocig  treatment  includes  the  use  of  cognitive  enhancers,  antipsychotics, 
antidepressants, anticonvultants, benzodiatzepines. Because of the many possible adverse effects, 
the medication should be chosen individually and with great care. There are still open questions and 
uncertaintes when it comes to the safety issues of using these pharmacotherapies in patients with 
dementia,  specially  the  recent  warnings  of  increase  in  cardiovascular  events  related  atypical 
antipsychotics need to be more closely investigated. 
Introduction
Dementia is a progressiv brain disorder, neurological disease that causes cognitive impairment and is 
often associated with aging. It affects 5 to 8 percent of people over age 65 and nearly 50 percent 
over age 85 (1). The incidense doubles every five years after the age of 60 years (2). In Norway over 
60 000 people suffer from dementia (3). The incidence and prevalence of dementia is increasing due 
to longer life expectancy of the world population. 
In  the  long  term  this  progressive  cognitive  impairment  causes  significant   physical,  sosial  and 
psychiatric disability.  It results in a restriction of daily activities, in most cases it leads to the need for 
care, and causes also significant problems, burden and distress in care givers (4). 
Non-cognitive symptoms are often present in dementia and play an important part for patients and 
caregivers.  Multiple studies have shown that BPSD affects the quality of life and is a major stress 
factor,  both  for  the  patient  with  dementia  and  for  the  caregiver.  Behavioral  and  psychological 
symptoms  of  dementia  are  associated  with  earlier  institutionalization  (5,6).  BPSD  are  varied  in 
relation to the stage of the demetia and to the aetiology, managing BPSD is an important challenge. 
Management  and  treatment  of  BPSD  include  both  non-pharmacologic  and  pharmacolocig 
interventions. 
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By getting better in recognition and management of BPSD is  one way to affect positively on the 
quality of life of the patients and their carers, and potentially delay the transition from home to an 
institution. The purpose with this paper is to review some of the recent litterature and to provide a 
summary of  BPSD and of the means and  medication available for managing and treating these 
behavioural disturbances. 
The central questions are:
What is dementia?
What is BPSD; symptoms, causes, assesment of these behavioural problems?
How can BPSD be managed and treated?
Methods
Medline,  PubMed  and  Cochrane  library  were  searched  using  keywords:  dementia,  behaviour 
symptom, disorder, BPSD, treatment. The search was limited mainly to meta-analysis, rewievs and 
guidelines  starting  from  year  2000.  Electronic  database  search  was  supplemented  with  hand 
searches of reference lists and authors.
4
Dementia
Decline in cognitive function is central in dementia. It is caused by pathology or damage in areas of 
brain that  take care of processing of information;  hippocampus,  thalamus,  temporal  areas.  Even 
minor damage in these areas can cause dementia, but also larger impairments in other parts of the 
brain can lead to dementia (3).
Dementia  can  be  divided  in  three  main  groups  by  it's  cause:  I)  primary  degenerative  dementia 
II)vascular dementia III) secondary dementia (3):
I Primary degenerative dementia
-Alzheimer disease
-Frontotemporal 
dementia
-Huntington disease
-Parkinson disease
-Lewy body dementia
-other more rare 
degenerative diseases
II Vascular dementia
-small vessel disease; 
lacunar state, Biswanger's 
disease
-since infarct, multiple 
infarcts
-hypoxic dementia
-other vascular diseases 
and dementia
-mixed dementia; vascular 
and Alzheimer disease
III Secondary dementia
-alcohol /alcoholism
-vitamine deficiencies 
(vit-B)
-infections of brain 
structures; encephalitis, 
HIV/AIDS, syphilis, 
herpes, borrelia
-Creutzfeldt-Jacob 
Disease (CJD)
-brain tumors
-head injury
-hematoma
-normal pressure 
hydrocephalus
-toxic exposure, 
metabolic and hormonal 
disorders
After excluding other reversible causes of cognitive impairment, there are four dementia syndromes 
which are most common and  account for about 90% of all cases. These are Alzheimer's disease (AD), 
vascular dementia (VaD), dementia with Lewy bodies (DLB), and fronto-temporal dementia (FTD). 
These four common diseases have different clinical characteristics, and there are diagnostic criteria 
for each of them. It is important to distinguish between the different forms of dementia because 
they require different approaches, treatment and management, and because some of the risk factors 
can be preventable (2,3,7,8,9).
Diagnostic evaluation
Taking medical history is central when diagnosing dementia; it should include the cognitive domains 
affected, the mode of onset, the pattern of progression and the impact on activities of daily living. 
Also  family  history,  past  medical  history,  educational  history  and  current  co-morbidities  are 
important,  and the clinical  history  should be supplemented by an independent  informant  when 
available (2,4).
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Dementia  can  be  accompanied  by  different  kinds  of  behavioural  and  psychological  symptoms. 
Assesment of behavioural and psychological symptoms of dementia is essential both for diagnosis 
and management, symptoms should be actively asked about from the patient and carer (2,4).
Diagnostic Criteria for Research for the ICD-10 Dementia (10).
G 1 Evidence of each of the following
G 1.1 A decline in memory, mild, moderate, severe
G 1.2 A decline in other cognitive abilities (judgment, thinking, planning, organizing),
mild, moderate, severe
G 2 Awareness of the environment (i.e., absence of clouding of consciousness)
G 3 Decline in emotional control or motivation or social behavior. At least one of thefollowing 
symptoms should be present:
G 3.1 emotional lability
G 3.2 irritability
G3.3 apathy
G 3.4 coarsening of social behavior
G 4 Symptoms in Criterion G1 should have been present for at least 6 months
General neurological and psysical examination should be performed on all patients. 
Laboratory screening with blood test should include complete blood cell count, Hb, sedimentation 
test,  electrolytes, calcium, glucose, renal and liver function tests, thyreoidea and parathyreoidea 
function tests. Supplementary test are often required after individual consideration e.g. vitamin-B12 
and serological tests for syphilis, borrelia, HIV (2,3,4).
Cognitive assesment should include a global cognitive measure (Mini-Mental State Examination) and 
can also include more detailed testing of memory, executive functions and instrumental functions 
(2).
It  is  recommended  to  use  structural  neuroimaging in  evaluation  of  every  patient  suspected  of 
dementia. For example surgically treatable lesions and vascular disease can be identified by CT, to 
increase  specificity  MRI  should  be  used.  SPECT  can  be  useful  supplement  when  diagnostic 
uncertainty remains, for example in diffenrential diagnosis between  AD and FTD (3,4).
Electroencephalography (EEG) may be useful adjunct but is seldom used in clinical practise. It should 
be  used  when  suspecting  CJD  or  transient  epileptic  amnesia.  CSF  analysis is  recommended  in 
patients with a clinical suspicion of certain diseases and atypical clinical presentations. In diagnostic 
doubt CSF total  tau,  phospo-tau and Ab42 can be helpful.  With family history  of  an autosomal 
dominant dementia genetic testing can be useful. ApoE genotyping is not recommended (2,3,4).
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Alzheimer's disease
AD is the most common cause of dementia (60%) among older adults. The major pathogenesis is the 
production and accumulation of beta-amyloid peptide,  the formation of neurofibrillary tangles of 
tau  protein,  oxidation  and  lipid  peroxidation,  glutaminergic  excitotoxicity,  inflammation,  and 
activation of the cascade of apoptotic cell death. These lead to neuron degeneration and synaptic 
loss. There are reduced number of cholinergic neurons in late AD; acetylcholine (ACh) is an important 
neurotransmitter in memory formation and loss of ACh activity correlates with the severity of AD (7, 
9).
AD can be seen as 2 types of disease when it comes to debut; one with early debut before 65 years 
of age (with more rapid progression), and the other type with late debut after 65 years. The natural 
course of AD averages 10 years. Typical for AD is insidious and slow onset, progressive course, and 
early  memory loss.   At  least  one other cognitive impairment  such as  apraxia,  agnosia,  language 
dysfunction, visuospatial disorder, as well  as executive dysfunction, must be seen. These  defects 
should make up a decline from the previous level  of cognitive functioning,  interfering with daily 
activities (7, 9,10).
Memory decline in AD is characterized as a storage deficit; material cannot be recalled with cue. 
Memory impairment for recent events is common whereas long-term memory remains intact in the 
early stage, but as AD progresses the patient is increasingly unable to recall more distant memories. 
Tthe motor signs are absent early in the course, as are sensory abnormalities,  seizures, and gait 
difficulties  too.  Behavioural  changes,  including depression,  anxiety,  apathy,  aggression,  agitation, 
wandering,  vocalization,  disinhibition,  and  abnormal  eating,  are  common  thereafter  and  cause 
caregiver stress as well as greater use of health care service. Neuroimaging with MRI shows atrophy 
specially in the hippocampus and temporal-lobe area (4,9).
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Cholinesterase  inhibitors  (ChEIs)  enhance  neuronal  transmission  by  increasing  the  availability  of 
acetylcholine  at  the  receptors.  This  effect  can  provide  temporary  stabilization  of  cognition   or 
reduction  in  the  rate  of  cognitive  decline,  and  improvement  of  symptoms  of  AD  (4,9,11,12). 
Memantin,  N-methyl-D-aspartate  (NMDA)  receptor  antagonist  targets  the  neurotransmitter 
glutamate,  a  chemical  messenger  in  the  brain  that  is  involved  in  normal  memory  and  learning 
processes.  leading  to  symptomatic  benefits  in  cognition,  behavior,  activities  of  daily  living,  and 
overall performance for patients ( 4,9,12).
Vascular dementia
Vascular dementia (VaD) counts for 20-25 % of dementias (13). There are several clinical syndromes 
of  vascular  dementia.  These  are  categorized  into  single  strategic  infarct  (single  brain  infarct 
damaging functionally critical  areas),  multi-infarct dementia,   lacunar state, Binswanger's  disease, 
genetic  forms  (e.g.,  cerebral  autosomal  dominant  arteriopathy  with  subcortical  infarcts  and 
leukoencephalopathy [CADASIL]) and hypoxic ischemic encephalopathy.  Mechanisms behind these 
clinical  syndromes  can  be  e.g.  hemorrhage,  ischemia/thrombosis,  vasospasm,  low  perfusion, 
hematologic and rheological problems (8). 
Patients may have different clinical presentations due to difference in etiology and mechanism, for 
example  the  onset  can  be  abrupt  or  insidious,  the  progression  stepwise,  fluctuating,  or  with 
continuous  worsening  (13).  However,  with  atherosclerotic  comorbidities  as  diabetes  mellitus, 
hypertension, coronary heart disease, typical cases of VaD are often seen; The onset of cognitive 
decline is either subtle or abrupt with psychomotor slowing, executive dysfunction, focal cognitive 
deficits  and  motor  signs.  By  neuroimaging  the  patient  must  demonstrate  some  form  of 
cerebrovascular  pathology:  vascular  lesions  that  may  differ  in  size  depending  on  the  degree  of 
vascular insult, lesions range from a single lacunar stroke to multiple cortico-subcortical strokes and 
periventricular white matter ischemia. Age is the most significant risk factor for any dementia; but 
other factors associated with health status earlier in life may predispose to developing VaD. For 
example,  atherosclerotic  risk  factors  such  as  smoking,  hypertension,  myocardial  infarctions, 
hyperlipidemia, and diabetes mellitus predispose older adults to cerebrovascular disease (CVD), and 
this can cause VaD (8). 
There is no spesific medication for VaD but treating involves use of medications and addressing the 
factors  behind  the  cardiovascular  disease  (8).  However,  ChEIs  may  be  considered  with  mild  to 
moderate severity of VaD; evidence indicates that (donepezil) ChEIs can improve cognitive symptoms 
and functional ability and is well tolerated (14,4). Cholinercig deficits in VaD are due to ischemia of 
basal forebrain nuclei and of cholinerg pathways (14).
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Dementia with Lewy bodies
10-15% of the patients with demens have DLB. It is a syndrome caused by abnormal microscopic 
deposits of protein (ubiquitin, alpha-synuclein), neuronal inclusion bodies called Lewy bodies, which 
destroy nerve cells.  Neurochemically there is a reduction of neurotransmitter ACh and dopamin. 
Lewy  bodies  can  cause  symptoms  typical  of  Parkinson  disease,  such  as  tremor,  rigidity  and 
bradykinesia, as well as dementia similar to that of Alzheimer disease. Lewy body dementia affects 
thinking, attention, and concentration more than memory and language.  The criteria for diagnosis of 
DLB are highly specific but not sensitive; core clinical features are fluctuating cognitive impairment, 
visual  hallucinations,  and  parkinsonism  (15,16).  Its  other  features  are  repeated  falls,  syncope, 
transient loss of consciousness, neuroleptic sensitivity, systematized delusion, hallucination of other 
modalities, REM sleep behaviour disorder, and depression. When making a diagnosis, the two most 
confusing  diseases  are  DLB  and  Parkinson's  disease  with  dementia  (PDD)  because  the  clinical 
features are so similar. If the onset of dementia is within 12 months of parkinsonism's onset, it is 
likely to be DLB.  By contrast,  if  the onset of  parkinsonism is  more than 12 months earlier  than 
dementia onset,  it  should be PDD. Patients  with PDD have parkinsonian features at  the time of 
dementia  diagnosis,  whereas  only  25-50% of  those  with  DLB have  parkinsonism at  the  time of 
diagnosis.  Patients with DLB usually have extrapyramidal  signs as postural  instability and masked 
face, whereas tremor is less prominent than among those with PDD (16). 
Rivastigmine  may  decrease  some  psychiatric  symptoms  associated  with  DLB,  patients  with  DLB 
treated  with  cholinesterase  inhibitors  show  improvement  in  cognition  and  neuropsychiatric 
symptoms  (4).  Levodopa/carbidopa  may  improve  motor  function  in  some  patients  with  DLB; 
however, in many patients this combination has no effect and may exacerbate psychiatric symptoms 
or  confusion. Selective  serotonin  reuptake  inhibitors  are  the  drugs  of  choice  in  depression. 
Antipsychotics should not be used for DLB patients (10,15,16).
Frontotemporal dementia
The clinical picture of frontotemporal dementia (FTD) is caused by degenerative disease affecting the 
frontal  and  temporal  lobes,  and  is  described  with  the  emphasis  on  prominent  personality  and 
behavioural  changes  with  less  prominent  memory  loss  early  in  the  course.  The  clinical  onset  is 
insidious and usually between 35-70 years of age. FTD is often misdiagnosed as personality disorders 
or late-onset psychiatric disorders. Behavioural  and emotional  changes are alway present as e.g. 
disinhibition, impulsivity, distractibility, loss of personal awareness, antisocial behaviour, hyperorality 
(e.g., excessive eating), social withdrawal, stereotyped or preservative behaviour, and speech output 
change (e.g., reduction / stereotype / echolalia). 50% of  patients have a family history of dementia in 
a first-degree relative. There are three principal clinical subtypes of FTD: a behavioral/dysexecutive 
(frontal)  variant  and  2  variants  with  prominent  language  impairments.  There  are  currently  no 
approved medications indicated for the treatment of frontotemporal dementia (4,17).
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Behavioral and Psychological Symptoms of Dementia
Behavioral  symptoms in   dementia  are  quite  common and often much more troubling  than  for 
example amnestic symptoms. These symptoms may even start before diagnosis of dementia is made 
(18). It is estimated that about 90% of patients with dementia will develop behaviour problems at 
some  point  during  the  illness.   These  symptoms  include  e.g.   agitation,  aggression,  delusions, 
hallucinations, and wandering, also depression and sleep disturbances can also occur with dementia. 
The prevalence of BPSD increases with disease severity. The presence of these symptoms leads to 
greater functional impairment in patients with dementia. Disruptive behaviour, specially agitation 
anf  aggression  commonly  precipitate  institutional  placement.  Intervention  is  important  because 
BPSD can respond to treatment more readily than cognitive and functional deficits do, and effective 
treatment can delay institutiolization. (6,12).
Delusions
Agitation/aggression
-Verbal
-Physical
Hallucinations
-Auditory
-Visual
Misidentifications
Depression
Anxiety
Euphoria/disinhibition
Apathy
Irritability
Aberrant motor behaviors
-Pacing
-Wandering
Restlessness
Nighttime behaviors (e.g., sundowning)
Appetite/eating changes
Table: BPSD
What causes BPSD?
The most important cause for BPSD is the illness itself and it's severity, the neurobiological changes 
go hand in hand with the progression of these symptoms. In AD the psychological  symptoms as 
depression and anxiety are more common in the early phase of the disease and behavioral problems 
in more advanced stage. In Changes in levels of the neurotransmitters in the CNS have relation to 
spesific types of BPSD.  Local loss of neurons in the brain and  the formation of neurofibrillary tangles 
for example, are related to apathy and psychotic behaviour (19). Other possible reasons behind the 
BPSD are misinterpretation (inviroment, caregiver, signals/cues), pain (bone, dental, skin breakdown, 
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rash), fear, fatigue, boredom, over/understimulating and  communication difficulties. Also delirium 
increases confusion. One important cause for aggression towards caregivers can be intimate care 
(toileting, bathing). Symptoms are often triggered by unmet needs and lack of understanding of the 
patient (20).
Assessing BPSD
It is not allways that behavioral problems have to be treated in patients with dementia. The need for 
treatment is related to the type and severity of the symptoms, and has to be evaluated individually. 
Assessing BPSD should begin with a few simple questions as: What exactly is the problem? Why is it a 
problem now; is it  a new problem, is there something new, changes in routines or enviroment? 
Whose problem is this; is it patient, visitors, family, caregivers, the staff, other residents that are 
conserned about or suffer because of the behaviour? Is there a safety risk either to the individual or 
someone else?
When assessing BPSD one should try to identify the reasons behind the problems, central in this is to 
interwiev  both  the  patient  and  the  caregivers.  Laboratory  screening  and  thorough  physical 
examination of  the individual  with dementia is  an important  part  of  assesment,  this  to rule out 
medical conditions and sensory deficits, identify co-morbidity and adverse effects of medication that 
could  cause  the  behavioural  disturbances.  There  should  be  evaluation  for  conditions  as  pain, 
constipation, delirium, unmet needs and physical invorement. The possibility of depression should 
not be forgotten, it is common in older adults including individuals with AD, and is often untreated. 
There  are  many  kind  of  neuropsychiatric  symptom  rating  scales  that  can  be  used  as  help  in 
assesment  e.g.  Neuropsychiatric  inventory  (NPI),  Behave  AD,  Geriatric  Depression  scale  (GDS), 
Cohen-Mansfield Agitation Inventory (11,19,21).
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Treatment of BPSD
The  management  of  BPSD  requires  a  comprehensive,  multimodal  approach  that  begins  with 
assessment  and  diagnosis.  Untreated  BPSD  can  contribute  to  premature  institutionalization, 
increased financial cost, decreased quality of life for both the caregiver and the patient, significant 
caregiver  stress,  stress  to  nursing  staff,  and  excess  disability  of  the  individual  with  dementia. 
Treatment and management of BPSD consists of two main measures, which are nonpharmacologic 
interventions and pharmacologic treatments (11,22).
Nonpharmacologic interventions
The nonpharmacological  interventions  should be tried first  before  drugs  are  used.  Enviromental 
manipulations can be crucially important. Caregivers can be taught strategies to reduce behavioral 
disturbances in patients with dementia. Use of validation therapy or reminiscence therapy and the 
use of therapeutic activities may bring positive effect (4,11,23,24). Nonpharmacologic interventions 
that can be tried by caregivers and staff e.g. in individuals with BPSD are (4,11):
Nonpharmacologic interventions for reducing behavioral disturbances  
Provide the patient with a predictable routine ( exercise, meals, and bedtime should be routine and 
punctual). 
Allow the patient to dress in his or her own clothing and keep possessions. 
Before performing all procedures and activities, explain them to the patient in simple language. 
Simplify all tasks; break complex tasks into steps and provide instructions for each step. 
Use distraction and redirection of activities to divert the patient from problematic situations. 
Ensure that comorbid conditions are optimally treated. 
Provide a safe environment (no sharp-edged furniture, no slippery floors or throw rugs, no 
obtrusive electric cords). 
Equip doors and gates with safety locks. 
Install grab bars by the toilet and in the shower. 
Use calendars, clocks, labels, and newspapers for orientation
to time. 
Use color-coded or graphic labels (on closets, table service, drawers) as cues for orientation in the 
home environment. 
Use lighting to reduce confusion and restlessness at night. 
Avoid glare from windows and mirrors, noise from a television, and household clutter. 
Reduce excess stimulation and outings to crowded places 
(overexposure to environmental stimuli can lead to agitation and disorientation). 
Consider using a day care program for patients with dementia. 
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Nonpharmacologic  interventions  for  behaviour  problems  in  AD  may  enable  a  reduction  in  the 
dosage, duration or complexity of required medication(14). For the reduction of neuropsychiatric 
symptoms,  behavioral  management  techniques  centered  on  individual  patients'  behavior  have 
shown to be succesfull (23). Numerious behavioral and psychosocial interventions have been tried, 
for  example  conditioning,  pet  therapy,  learning  experience,  music/stimulation  therapy,  aroma 
therapy. In some studies these show positive effect with behaviour modification, but often these 
have no long term effect. More studies are required to determine the effectiveness of these various 
therapies (20,22,23,25).
Pharmacologic treatment
There  is  evidence  that  pharmacotherapies  are  used  frequently  to  treat  BPSD,  even  when 
recommendations suggest the use of nonpharmacologic therapies first. Pharmacologic interventions 
are necessary when nonpharmacologic strategies fail to reduce behavioral symptoms sufficiently. As 
pharmacolocig  treatment  it  has  been  tried  the  use  of  cognitive  enhancers,  antipsychotics, 
antidepressants, anticonvultants, benzodiatzepines (11,22).
The psychotropic agent should be initiated in a lowest possible dosage that should be increased 
slowly, the patient should be monitored for side effects. Until  adequate response occurs or side 
effects emerge, the dosage should be increased. Also potential drug interactions should be kept in 
mind. The dosage of psychotropic agent should be reduced after behavioral disturbances have been 
controlled for four to six months; this to determine whether continued pharmacotherapy is required 
(22).
The choice of psychopharmacologic agent is dictated by specific target symptoms. Some behaviors, 
such  as  wandering  and  pacing,  frquent  repetition,  are  not  amenable  to  drug  therapy.  Apathy, 
depression, anxiety, hallucinations, delusions, agitation, and aggression are target symptoms that are 
more  likely  to  respond  to  pharmacotherapy  .  Pharmacotherapy  could  be  considered  a  first-line 
therapy in the context of severe depressive symptoms, psychosis, and aggression, which place the 
patient or others at risk of harm (11,22).
Cognitive Enhancers
The  cognitive  enhancers  are  the  cholinesterase  inhibitors  (ChEIs)  donepezil,  galantamine,  and 
rivastigmine, and the NMDA receptor antagonist memantine.  There is increasing evidence that these 
agents have beneficial effects also on behaviour; Cholinesterase inhibitors may improve BPSD, this 
mainly  in  mild  and  non-psychotic  behaviour  disorders.  Use  of  a  psychotropic  agent  may  be 
necessary,  if  behavioral  disturbances  continue  to  exist  despite  cholinesterase  inhibitor  therapy. 
There is a risk of adverse effects when using ChEIs, including nause, vomiting diarrea. Memantine is 
rapported to be better tolerated (11,21,22,26).
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Antipsychotics
The antipsychotics are the best-studied pharmacologic interventions for BPSD; several systematic 
reviews have concluded that the evidence for their efficacy is better than that for any other drug 
class.  Antipsychotics  are  among the medications  most  commonly  used to treat  BPSD.  Agitation, 
aggression,  psychosis,  and  sleep  disturbance  are  the  symptoms  most  likely  to  respond  to 
antipsychotics. But especially in residential and nursing homes overprescribing has however become 
a problem; up to 40% of people with dementia may be taking antipsychotics, often inappropriately 
and with little monitoring. This is problematic specially because of the adverse effects as increased 
risk of falls and drowsines, parkinsonism, akathisia, tardive dyskinesia (6,21,22,25).
Metaanalyses of typical antipsychotics such as haloperidol suggest significant benefit, however, the 
side  effectcs  limit  the  use  of  haloperidol.  It  can  be associated with severe  effects  involving the 
cholinerg,  cardiovascular,  and extrapyramidal  system. It  is  likely owing to the fact that dementia 
patients  are  at  significant  risk  for  developing  for  example  extrapyramidal  symptoms  such  as 
parkinsonism  and  tardive  dyskinesia,  that  typical  antipsychotic  use  has  declined.  Typical 
antipsychotics should be second line therapy, mainly for patients who don't tolerate or respond on 
atypical antipsychotics (11,21,22,24).
There have been several large, well-designed, placebocontrolled trials of atypical antipsychotics, also 
called  second-generation antipsychotics.  These include  risperidone,  olanzapine,  quetiapine,  and 
aripiprazole. Atypical antipsychotics are typically licensed for the treatment of schizophrenia, acute 
psychosis and other mental disorders such as bipolar disorder. The off-label use of these agents in 
the control of non-schizophrenia psychosis or non-psychotic behavioural problems has become more 
common  and  these  agents  have  been  widely  used  to  treat  the  BPSD.  They  are  usually  better 
tolerated than the typical neuroleptics. (11,20,24,27)
Some systematic reviews and metaanalyses have questioned the efficacy of the atypicals, but more 
often  it  is  suggested  significant  benefits  greater  than  placebo;  this  especially  and  mainly  for 
risperidone (significant in aggression and psychotic symtoms)  and in some extension for olanzapine 
(benefit in aggression and anxiety) (6). An average dosage of 1 mg risperidone daily is significantly 
more effective than placebo and as effective as haloperidol, but the advantage is that it is less likely 
to cause extrapyramidal symptoms than haloperidol. Olanzapine with dosage of 5 to 10 mg daily has 
also  shown  to  be  significantly  more  effective  than  placebo.  Olanzapine  use  is  assosiated  with 
sedation and incoordination at all doses (6,12,27).
Recent findings from randomised,  controlled clinical  trials  have cast  new doubt on the safety of 
atypical antipsychotics in treating BPSD; it was reported findings in meta-analysis on overall mortality 
and it was given warning of an increased risk of cardiovascular events, CVAEs (stroke, TIA, cerebral 
ischaemia), the first time was in 2002. The warning was at the beginning given about an increased 
risk of CVAEs in dementia patients treated with risperidone, but later, the following years, similar 
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warnings  have  been  released  for  olanzapine  and  subsequently  for  all  the  available  atypical 
antipsychotics. However, observational studies offer compelling data that typical antipsychotics are 
as likely to be associated with increased risks of  CVAEs and mortality,  when compared with the 
atypical antipsychotics, and there hasn't been significant difference . The increased risk for death and 
CVAEs could only  be  seen when atypical  antipsychotics  were combined in  a  meta-analysis  (15). 
According to the best available evidence at the time being, can atypical antipsychotics still be used 
for  severe  agitation,  aggression,  and psychosis.  Individual  patient  characteristics,  benefits  of  the 
therapy and risk factors should first be considered. More studies are required in the future to clear 
out risk of CVAEs (1, 22,27,28,29).
 
There  are  a  few randomized controlled trials  about  the behavioral  impact  of  discontinuation of 
antipsychotic use in people with dementia in the long-term care institutions. The result of these 
studies indicate that the antipsychotic discontinuation is likely to be safe intervention and usually 
don't cause significant worsening of behavior. Thereby there does not seem to be any obvious need 
for long-term treatment. However it is important to take into account the baseline dose; patients 
with  high  dose  on  antipsychotic  drug  at  baseline  have  greater  likelihood  of  exarcerbation  of 
behavioral symotoms and thereby need close monitoring. Patients who were using relatively low 
doses of antipsychotics were more likely to remain stable or even improve after drug discontinuation 
(30,31). Also patients with lower baseline score in Neuropsychiatric Inventory (NPI) Questionnaire 
seem to be less likely to develop marked behavioral problems when stopping antipsychotic drug 
therapy (31, 32).
Antidepressants
In AD patients depressive symptoms are common , and antidepressants have been studied both for 
the treatment of depression and other BPSD as agitation and aggression. There have been several 
RCTs  of  antidepressants;  tricyclics,  SSRIs  and  other  antidepressants.  Antidepressants  were 
significantly  better  than  placebo  in  treatment  of  depression.  Several  RCTs  have  examined 
antidepressants used to treat agitation. Tricyclics are not recommended because of the higher risk 
for side effects, SSRIs are relatively well tolerated. In some studies only citalopram have shown to be 
significantly better than placebo, and its use was in some degree associated with improvements in 
agitation, aggression, and psychosis (20, 21).
Reasonably  good  data  have  indicated  that  antidepressants,  especially  the  SSRIs,  are  safe  and 
effective for the treatment of depression in AD, but more data are required to determine the efficacy 
for the treatment of agitation and other BPSD (20, 21).
Anticonvulsants
Selective anticonvulsants have been used to treat patient with dementia,  mainly when psychotic 
behavior  results  in  aggression  and  agitation.  RCTs  have  studied  carbamazepine  and  valproate 
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treatment. Carbamazepine seems to have significant benefits for agitation and aggression, but there 
is relatively high risk forf drug-drug interactions and side effects. Also its therapeutic window is quite 
narrow (9,12).
It  was  earlier  hoped  that  the  use  of  valproate  would  represent  a  safer  and  better-tolerated 
alternative than carbamazepine. Even if in some studies it has shown benefit versus placebo, in many 
RCTs the results were all negative. Of greater concern is the tolerability of valproate found in studies; 
use of valproate has shown high rates of adverse events, e.g.  thrombocytopenia, whereas lower 
dosages of valproate were ineffective, higher dosages were associated with an unacceptable rate of 
adverse events. Other anticonvulsants (gabapentin, topiramate, lamotrigine) have been examined 
for BPSD, the evidence is still insufficient for recommendations (22).
Benzodiazepines
Several studies have been made about benzodiazepines, including oxazepam, diazepam, alprazolam, 
and lorazepam. Benzodiazepines  cause tolerance and dependence in long-term use, and even short-
term regular use in the elderly is associated with significant adverse effects as sedation, falls, and 
cognitive impairment.  Guidelines tend to relegate  their  use to "as-needed/emergency" use only. 
Evidence  for  the  use  of  benzodiazepines  in  these  circumstances  is  provided  by  comparing 
intramuscular  olanzapine and lorazepam with placebo for  the management of acute agitation in 
patients with dementia. Both medications were significantly more effective than placebo, with no 
differences in adverse events (11,22,24). 
Other Pharmacologic Treatments
There  has  been  proposed  noradrenergic  mechanisms  for  BPSD  and  thereby  the  beta  blockers 
propranolol and pindolol have been studied for agitation and aggression. Studies have shown either 
limited effect  or benefits that appear to diminish over time. Use of beta blockers in  frail elderly is 
also limited by contraindications because of the potential for adverse events as hypotension and 
bradycardia (22).
Also  various  other  pharmacologic  approaches  for  BPSD  have  been  studied.  These  studies  have 
included  buspirone,  a  nonbenzodiazepine  serotoninergic  anxiolytic,  preparations  of  estrogen, 
dronabinol for anorexia in dementia and melatonin for sleep disturbances in patients with AD. The 
results have either been negative or insufficient to allow conclusions about the effects or safety (22).
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Figure. Recommended Algorithm for Management of Neuropsychiatric Symptoms of Dementia (21).
SSRI indicates selective serotonin reuptake inhibitor. 
*Music therapy, aromatherapy, pet therapy, or other approaches. 
Caution is advised in patients with dementia with Lewy bodies.
Norwegian recommendations for treatment of BPSD
There is concensus with the overall international recommendations about assesment of BPSD, and 
about the importance of nonpharmacologic interventions being the primary choice in managing the 
behavioral  symptoms.  Pharmacolocig  treatment  may  be  iniated  if  no  results  are  gained  with 
nonpharmacologic means, and the medication should be chosen by the target symptoms and after 
careful individual evaluation of the patient (33).
Antipsychotics  should  only  be  used  if  severe  behaviour  disorders  with  aggression,  agitation  or 
psychotic symptoms, then risperidon should be the first choice. Use of older antipsychotics is not 
recommendated, except in rare cases haloperidol may carefully be tried. In DLP antipsychotics are 
contraindicated (33).
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Initiatial dosage recommendated for risperidon is  0,25 mg 1x2 daily, can be adjusted individually up 
to 0,5 mg 1x2;  the latter is  described to be the optimal dosage for most of the patients. Some 
patients may need even higher dosage (1mgx2). Observation of effect and adverse effects is needed 
continually. If no effect is seen after 4-6 weeks from initiation of risperidon, the treatment should not 
be  continued  with.  The  dosage  of  psychotropic  agent  should  be  reduced  after  behavioral 
disturbances have been controlled 3 months (33).
SSRI  is  the  first-line  choice  for  pasients  with  fier,  anxiety  or  depression,  which  can  be  seen as 
irritability  of  aggression.  Cholinesterase  inhibitors  should  be  the  first-line  choice  in  any  type  of 
dementia when visual hallucinations, and also for other behaviour symptoms in patients with DLP. 
Anticonvultants carbamazepin and valproate can be tried if severe aggression and agitation, in cases 
where there is no respond for other recommendated pharmacotherapies (33).
Conclusions and discussion
Behavioral and psychological symptoms are fairly common among individuals with dementia, and 
benefit from considered therapeutic interventions. Intervention effective on one symptom may not 
be effective for another. The nonpharmacologic interventions should allways be the first choice. 
Both medication and nonpharmacologic interventions reduce severity of the symptoms but rarely 
eliminate the target  behavior.  In treating dementia patients with severe and complex symptoms 
psychotropic medication has it's place. In any case, it is important to balance the benefits and risk 
when considerating medication, all the  pharmacologicals used for BPSD have adverse effects which 
can be dangerous and even fatal for a frail and fragile elderly patient with dementia. One central 
point in pharmacologic treatment is regular, continous observation and reassesment after initiation. 
The initiation of pharmacologic treatment requires individual, critical assessment. For the clinician 
this can be a rather difficult task in the middle of the jungle of adverse effects and the recent safety 
warnings for increased risk of cardiovascular events in antipsychotics. Even if the effectiveness of 
atypical antipsychotics is somewhat limited, they may have an important role in treatment of BPSD. 
More controlled trials are needed to establish efficacy of specially nonpharmacologic interventions, 
which should allways be tried before starting with medication. But there are also still  many open 
questions and uncertaintes when it comes to effectiveness of pharmacotherapies used for BPSD in 
patients with dementia for the safety issues concerning atypical antipsychotics and; these need to be 
more closely investigated. 
Pharmacolocig treatments of BPSD is not ment to be a life-long treatment, but there is still a lot of 
antipsychotic usage in elderly dementia patients that is inappropriate; the medication is used for 
chronic sedation purposes, over weeks and months, and even longer. This can partly be due to the 
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fact that the behaviour symptoms are exhausting for the caregivers and the staff in nursing homes. 
The institutions may also be under staffed. And the clinicians can have inadequate  knowledge and 
skills for treating the elderly patient with dementia. It is not only controlled trials that are needed in 
the future, there should also be greater investment in planning of the health care system and the 
care  of  the  elderly,  and  in  education  of  the  caregivers  and  health  personal  in  management  of 
dementia and BPSD.
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